The mission is quiet, but not still. Here's what the ship’s activity tells us about Phase 2 of the search. Gavin Newsom's ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

OKYO Pharma (NASDAQ:OKYO) stock jumped 14% Wednesday after announcing encouraging Phase 2 clinical trial results for urcosimod, their investigational drug aimed at neuropathic corneal pain (NCP). The ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

After the Grenfell fire there are many lessons to be learned. Architects and manufacturers should be able to demonstrate they ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

It’ll be the 5th and 6th ones they’ve built so far. This partnership has been in the making since 2022, and Bright Community Trust broke ground on their first houses here in Gainesville in 2024. The ...

A local Catholic high school is continuing progress on their new athletic facility, which broke ground earlier this year.

Thunderbolts* introduced one of the MCU's most powerful heroes, but a new theory suggests his abilities are connected to an age-old villain.

Amirco Properties, a real estate company, is expected to break ground on the 4-acre, multi-building development—dubbed ...